Zoetis Inc.

Listed Company

ZTSCIK 0001555280NYSELarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$9.47B

Net Income

$2.67B

Total Assets

$15.50B

Equity

$3.33B

Shares Out

422.13M

Op. Cash Flow

$2.90B

Business

Zoetis Inc. develops, manufactures and commercializes animal health products and related services focused on predicting, preventing, detecting and treating illness across companion animals and livestock. Its main offerings include medicines, vaccines, diagnostic instruments and reagents, biodevices, genetic tests and precision animal-health services. The company operates in two reporting segments—United States and International—and also provides contract manufacturing through its Client Supply Services and maintains R&D and manufacturing organizations that support product lifecycle innovation. Zoetis markets products directly in about 45 countries and sells in over 100 countries through veterinarians, distributors, retail and e-commerce channels.

Summary from filing dated 2025-02-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	9,467	9,256	8,544	8,080	7,776
Cost of Sales	2,666	2,719	2,561	2,454	2,303
Selling, general and administrative expenses	2,378	2,318	2,151	2,009	2,001
Research and development expenses	698	686	614	539	508
Amortization of intangible assets	128	141	149	150	161
Restructuring charges and certain acquisition and divestiture-related costs	51	53	53	11	—
Interest expense, net of capitalized interest	222	225	239	221	224
Other (income)/deductionsnet	−36	−19	−159	40	48
Income before provision for taxes on income	3,360	3,133	2,936	2,656	2,488
Provision for taxes on income	687	637	596	545	454
Net income before allocation to noncontrolling interests	2,673	2,496	2,340	2,111	2,034
Less: Net income/(loss) attributable to noncontrolling interests	0	10	−4	−3	−3
Net income attributable to Zoetis Inc.	2,673	2,486	2,344	2,114	2,037
Basic (in dollars per share)	6.03	5.47	5.08	4.51	4.29
Diluted (in dollars per share)	6.02	5.47	5.07	4.49	4.27
Basic (in shares)	443	454	461	469	474
Diluted (in shares)	444	455	462	470	477
Dividends declared per common share	2.03	1.8	1.56	1.35	1.08

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	2,312	1,987	2,041	3,581	3,485
Accounts receivable, less allowance for doubtful accounts of $16 in 2025 and $18 in 2024	1,590	1,316	1,304	1,215	1,133
Inventories	2,430	2,306	2,564	2,345	1,923
Other current assets	436	377	434	365	389
Total current assets	6,768	5,986	6,343	7,506	6,930
Property, plant and equipment, less accumulated depreciation of $2,925 in 2025 and $2,635 in 2024	3,681	3,391	3,204	2,753	2,422
Operating lease right-of-use assets	288	219	230	220	181
Goodwill	2,767	2,724	2,759	2,746	2,682
Identifiable intangible assets, less accumulated amortization	998	1,127	1,338	1,380	1,474
Noncurrent deferred tax assets	637	540	206	173	100
Other noncurrent assets	328	250	206	147	111
Total assets	15,500	14,200	14,300	14,900	13,900
Current portion of long-term debt	0	1,350	0	1,350	0
Accounts payable	487	433	411	405	436
Dividends payable	232	224	198	174	154
Accrued expenses	852	746	683	682	710
Accrued compensation and related items	410	441	382	300	392
Income taxes payable	147	93	110	157	38
Other current liabilities	107	125	102	97	67
Total current liabilities	2,235	3,412	1,889	3,167	1,797
Long-term debt, net of discount and issuance costs	9,042	5,220	6,564	6,552	6,592
Noncurrent deferred tax liabilities	139	167	146	142	320
Operating lease liabilities	196	174	188	186	151
Other taxes payable	276	272	271	258	257
Other noncurrent liabilities	248	222	237	217	239
Total liabilities	12,136	9,467	9,295	10,522	9,356
Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 424,927,535 and 448,473,073 shares outstanding at December 31, 2025 and 2024, respectively	5	5	5	5	5
Treasury stock, at cost, 76,963,708 and 53,418,170 shares of common stock at December 31, 2025 and 2024, respectively	−10,685	−7,445	−5,597	−4,539	−2,952
Additional paid-in capital	1,101	1,182	1,133	1,088	1,068
Retained earnings	13,744	11,968	10,295	8,668	7,186
Accumulated other comprehensive loss	−834	−940	−839	−817	−764
Total Zoetis Inc. equity	3,331	4,770	4,997	4,405	4,543
Equity attributable to noncontrolling interests	0	0	−6	−2	1
Total equity	3,331	4,770	4,991	4,403	4,544
Total liabilities and equity	15,467	14,237	14,286	14,925	13,900

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	487	497	491	465	448
Share-based compensation expense	83	74	60	62	58
Asset write-offs and asset impairments	47	31	46	53	47
Net loss/(gain) on sale of businesses, excluding transaction costs	3	23	−118	0	0
Provision for losses on inventory	68	97	115	76	46
Deferred taxes	−52	−338	−61	−286	−80
Settlement of derivative contracts	11	0	0	—	—
Other non-cash adjustments	−8	−6	−8	13	0
Accounts receivable	−236	−61	−102	−137	−155
Inventories	−199	−40	−361	−486	−366
Other assets	−165	52	−95	35	−7
Accounts payable	46	31	13	−29	−17
Other liabilities	85	114	67	−180	227
Other tax accounts, net	61	−17	−34	98	−25
Net cash provided by operating activities	2,904	2,953	2,353	1,912	2,213
Capital expenditures	−621	−655	−732	−586	−477
Acquisitions, net of cash acquired	−24	−8	−155	−312	−14
Purchase of investments	−7	−5	−4	−9	−12
(Payments of)/proceeds from derivative instrument activity, net	−93	62	12	23	44
(Payment of)/proceeds from sale of businesses, net of cash sold and working capital adjustments	−4	293	96	0	0
Other investing activities	1	−2	6	0	−1
Net cash used in investing activities	−748	−315	−777	−883	−458
(Decrease)/increase in short-term borrowings, net	0	−3	1	2	−4
Principal payments on long-term debt	−1,350	0	−1,350	0	−600
Proceeds from issuance of long-term debtsenior notes, net of discount	1,848	0	0	1,348	0
Proceeds from issuance of convertible debt	2,000	0	0	—	—
Payment of debt issuance costs	−43	0	0	−10	0
Payment of premium on capped calls related to convertible debt	−187	0	0	—	—
Payment of consideration related to previous acquisitions	0	−5	−3	−1	−6
Share-based compensation-related proceeds, net of taxes paid on withholding shares	−11	−8	27	−38	−35
Purchases of treasury stock, including excise taxes paid	−3,235	−1,858	−1,092	−1,594	−743
Cash dividends paid	−889	−786	−692	−611	−474
Other financing activities	−3	0	0	—	—
Net cash used in financing activities	−1,870	−2,660	−3,109	−904	−1,862
Effect of exchange-rate changes on cash and cash equivalents	39	−32	−7	−29	−12
Net increase/(decrease) in cash and cash equivalents	325	−54	−1,540	96	−119
Income Taxes Paid, Net	715	892	754	638	548
Interest, net of capitalized interest	261	274	295	242	253
Capital expenditures	4	3	2	3	6
Excise tax accrued on net share repurchases, not paid	31	17	10	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro